Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tregs in T1DM
NCT06708780Phase 1Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous regulatory T cells in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Number of Participants with adverse events, laboratory abnormalities and other signs of toxicity at 1 year. Started Apr 2023; status: recruiting.
02
Drugs
autologous regulatory T cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06708780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708780.